Invenomic Fund Investor Class shares BIVRX

Medalist Rating as of | See Invenomic Investment Hub
  • NAV / 1-Day Return 15.96  /  −1.18 %
  • Total Assets 591.3M
  • Adj. Expense Ratio
    2.490%
  • Expense Ratio 3.290%
  • Distribution Fee Level High
  • Share Class Type No Load
  • Category Long-Short Equity
  • Investment Style Small Value
  • Min. Initial Investment 5,000
  • Status Limited
  • TTM Yield 2.35%
  • Turnover 197%

USD | NAV as of Jul 10, 2026 | 1-Day Return as of Jul 10, 2026, 12:58 AM GMT+0

Morningstar’s Analysis BIVRX

Will BIVRX outperform in the future?

Get our overall rating based on a fundamental assessment of the pillars below.

null Morningstar Automated Analysis

Morningstar Automated Analysis

Summary

Invenomic Investor holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings BIVRX

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 8.5
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Us Dollar Broker

72.86 707M
Cash and Equivalents

First American Government Obligs X

7.12 69M
Cash and Equivalents

Australian Dollar

4.27 41M
Cash and Equivalents

Lyft Inc Class A

3.15 31M
Technology

Workday Inc Class A

3.11 30M
Technology

Fiserv Inc

3.06 30M
Technology

Salesforce Inc

3.01 29M
Technology

Global Payments Inc

2.88 28M
Industrials

Fidelity National Information Services Inc

2.33 23M
Technology

Ingredion Inc

2.10 20M
Consumer Defensive

Sponsor Center